Stock listing
TSXV:TLT Theralase Technologies Inc. Stock
Home listing (TSXV) of Theralase Technologies Inc.
Follow Theralase Technologies Inc. into a list and get an email when it puts out news.
Share price · TSXV:TLT
$0.19 CAD 0.00 (0.0%)
Close on Nov 6, 2026
- Day range
- $0.185 – $0.20 CADNov 6, 2026
- Volume
- 101,753 sharesNov 6, 2026
- Market cap
- $58.99M CADAt the close on Nov 6, 2026 · price × 310.5M shares outstanding
- 52-week range
- $0.145 – $0.41 CADLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- $44,564 CADMedian day 145,631 shares · last 3 months, Aug 6, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:TLT · Home | $0.19 CAD | 0.00 (0.0%) | 101,753 | $0.20 | $0.20 | $0.185 | $0.19 | Close on Nov 6, 2026 |
| OTC:TLTFF | $0.134 USD | 0.000 (-0.1%) | 179,500 | $0.134 | $0.134 | $0.131 | $0.134 | Close on Nov 6, 2026 |
| Frankfurt:TTX | €0.108 EUR | +0.002 (+1.9%) | — | €0.108 | €0.108 | €0.108 | €0.106 | Close on Nov 6, 2026 |
| Stuttgart:TTX | €0.112 EUR | -0.003 (-2.6%) | — | €0.115 | €0.115 | €0.107 | €0.115 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · TSXV:TLT · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.19 | 0.00 | 0.0% | $0.20 | $0.20 | $0.185 | 101,753 | |
| $0.19 | +0.005 | +2.7% | $0.185 | $0.19 | $0.185 | 145,631 | |
| $0.185 | +0.005 | +2.8% | $0.19 | $0.19 | $0.185 | 45,687 | |
| $0.18 | -0.015 | -7.7% | $0.205 | $0.205 | $0.18 | 40,902 | |
| $0.195 | +0.015 | +8.3% | $0.195 | $0.195 | $0.195 | 1,285 | |
| $0.18 | -0.02 | -10.0% | $0.185 | $0.195 | $0.175 | 139,043 | |
| $0.20 | 0.00 | 0.0% | $0.205 | $0.205 | $0.20 | 23,500 | |
| $0.20 | 0.00 | 0.0% | $0.205 | $0.205 | $0.20 | 39,890 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.21 | $0.19 | 113,762 | |
| $0.20 | -0.01 | -4.8% | $0.195 | $0.20 | $0.195 | 27,859 | |
| $0.21 | -0.01 | -4.5% | $0.22 | $0.25 | $0.205 | 512,773 | |
| $0.22 | +0.03 | +15.8% | $0.19 | $0.23 | $0.19 | 508,800 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 26,200 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 10,000 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 12,200 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.18 | 43,600 | |
| $0.19 | 0.00 | 0.0% | $0.20 | $0.20 | $0.19 | 62,100 | |
| $0.19 | +0.01 | +5.6% | $0.19 | $0.19 | $0.18 | 68,500 | |
| $0.18 | +0.005 | +2.9% | $0.18 | $0.19 | $0.18 | 184,600 | |
| $0.175 | 0.00 | 0.0% | $0.175 | $0.18 | $0.175 | 132,102 | |
| $0.175 | -0.005 | -2.8% | $0.175 | $0.18 | $0.175 | 216,042 | |
| $0.18 | +0.005 | +2.9% | $0.185 | $0.185 | $0.18 | 27,205 | |
| $0.175 | -0.01 | -5.4% | $0.185 | $0.19 | $0.175 | 162,540 | |
| $0.185 | +0.01 | +5.7% | $0.185 | $0.185 | $0.18 | 71,520 | |
| $0.175 | -0.005 | -2.8% | $0.18 | $0.18 | $0.175 | 9,652 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.17 | 176,594 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.175 | 135,050 | |
| $0.18 | +0.005 | +2.9% | $0.18 | $0.18 | $0.18 | 31,668 | |
| $0.175 | 0.00 | 0.0% | $0.18 | $0.18 | $0.17 | 63,849 | |
| $0.175 | 0.00 | 0.0% | $0.18 | $0.18 | $0.17 | 71,411 | |
| $0.175 | 0.00 | 0.0% | $0.18 | $0.18 | $0.17 | 76,608 | |
| $0.175 | -0.005 | -2.8% | $0.18 | $0.18 | $0.175 | 81,078 | |
| $0.18 | -0.005 | -2.7% | $0.185 | $0.185 | $0.18 | 306,004 | |
| $0.185 | 0.00 | 0.0% | $0.19 | $0.19 | $0.18 | 178,972 | |
| $0.185 | -0.005 | -2.6% | $0.185 | $0.19 | $0.18 | 315,420 | |
| $0.19 | +0.005 | +2.7% | $0.185 | $0.19 | $0.185 | 64,657 | |
| $0.185 | +0.005 | +2.8% | $0.185 | $0.185 | $0.185 | 14,584 | |
| $0.18 | 0.00 | 0.0% | $0.195 | $0.195 | $0.18 | 305,125 | |
| $0.18 | -0.01 | -5.3% | $0.185 | $0.19 | $0.18 | 184,573 | |
| $0.19 | +0.005 | +2.7% | $0.185 | $0.19 | $0.185 | 30,127 | |
| $0.185 | -0.005 | -2.6% | $0.19 | $0.19 | $0.18 | 576,919 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 132,352 | |
| $0.19 | +0.005 | +2.7% | $0.19 | $0.19 | $0.19 | 7,227 | |
| $0.185 | +0.005 | +2.8% | $0.185 | $0.185 | $0.185 | 177,002 | |
| $0.18 | -0.01 | -5.3% | $0.185 | $0.19 | $0.18 | 197,631 | |
| $0.19 | +0.005 | +2.7% | $0.18 | $0.20 | $0.18 | 278,002 | |
| $0.185 | +0.005 | +2.8% | $0.18 | $0.185 | $0.18 | 250,027 | |
| $0.18 | -0.005 | -2.7% | $0.185 | $0.185 | $0.18 | 229,049 | |
| $0.185 | +0.005 | +2.8% | $0.18 | $0.185 | $0.18 | 248,315 | |
| $0.18 | -0.005 | -2.7% | $0.18 | $0.185 | $0.18 | 326,577 | |
| $0.185 | -0.005 | -2.6% | $0.19 | $0.195 | $0.18 | 496,508 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.185 | 559,121 | |
| $0.19 | +0.005 | +2.7% | $0.185 | $0.195 | $0.185 | 326,571 | |
| $0.185 | -0.005 | -2.6% | $0.195 | $0.195 | $0.185 | 344,702 | |
| $0.19 | +0.01 | +5.6% | $0.18 | $0.20 | $0.18 | 375,405 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.175 | 289,752 | |
| $0.18 | -0.005 | -2.7% | $0.185 | $0.185 | $0.18 | 303,825 | |
| $0.185 | 0.00 | 0.0% | $0.18 | $0.185 | $0.18 | 554,474 | |
| $0.185 | 0.00 | 0.0% | $0.185 | $0.185 | $0.18 | 801,028 | |
| $0.185 | +0.01 | +5.7% | $0.18 | $0.19 | $0.18 | 973,711 | |
| $0.175 | -0.015 | -7.9% | $0.19 | $0.19 | $0.175 | 1,071,834 | |
| $0.19 | -0.05 | -20.8% | $0.20 | $0.205 | $0.185 | 1,759,937 | |
| $0.24 | -0.025 | -9.4% | $0.26 | $0.26 | $0.238 | 285,096 | |
| $0.265 | +0.005 | +1.9% | $0.26 | $0.265 | $0.26 | 76,860 | |
| $0.26 | 0.00 | 0.0% | $0.265 | $0.27 | $0.26 | 17,000 |
- Ticker
- TSXV:TLT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TSXV
- Currency
- CAD
What changed lately
Latest news release · Oct 26, 2026
Theralase Provides Bladder Cancer Clinical Study Update
Latest earnings call · Sep 3, 2026
Theralase Technologies (TSXV:TLT) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 22, 2026
Investor Presentation (October 2026)
Investor deck · 16 slides
Calls
Replays
Theralase Technologies (TSXV:TLT) Q2 2026 Earnings Call
Thu, Sep 03, 2026 · 11:00 AM ET
Watch Transcript
Latest news
Theralase Provides Bladder Cancer Clinical Study Update
Oct 26, 2026
Closed $0.20 (-4.8%) on Oct 26, 2026
Theralase(R) to Present at ThinkEquity Conference
Oct 9, 2026
Closed $0.175 (0.0%) on Oct 9, 2026
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Sep 18, 2026
Closed $0.185 (-2.6%) on Sep 18, 2026
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Sep 15, 2026
Closed $0.18 (0.0%) on Sep 15, 2026
Theralase(R) Releases Q2 2026 Financial Statements
Aug 28, 2026
Closed $0.18 (-2.7%) on Aug 31, 2026
Theralase(R) Closes C$3.6 Million Brokered Financing
Aug 24, 2026
Closed $0.19 (0.0%) on Aug 25, 2026
Theralase(R) Announces $5 Million Brokered LIFE Offering
Aug 10, 2026
Closed $0.19 (-20.8%) on Aug 11, 2026
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Aug 4, 2026
Closed $0.27 (-5.3%) on Aug 4, 2026
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Jun 30, 2026
Closed $0.275 (+7.8%) on Jul 2, 2026
Theralase(R) Lists Warrants on the TSXV
Jun 3, 2026
Closed $0.225 (0.0%) on Jun 3, 2026
Financings
Private placement of units
Sep 18, 2026
Closed: C$3.56M in the latest tranche · C$0.24 a unit · 1 warrant at C$0.32 · Research Capital Corporation
Dealers: Research Capital Corporation (lead)
Insiders: An aggregate of 116,250 Units, representing gross proceeds of $27,900, were issued to certain insiders of the Company
Use of proceeds: GLP toxicology studies for intravenous Rutherrin in cancers and topical Ruvidar for cold sores; working capital and general corporate purposes
Announced Aug 10, 2026 · Closed Aug 24, 2026 · Closed Aug 28, 2026 · Closed Sep 18, 2026
Private placement of units
Apr 10, 2026 · US$1.2M
Closed: C$1.67M raised · C$0.26 a unit · 1 warrant at C$0.36 for 60 months · free to trade Aug 11, 2026
Insiders: An aggregate of 937,400 Units, representing gross proceeds of $243,724, were issued to certain insiders
Use of proceeds: Phase II NMIBC CIS clinical study, GLP toxicology analysis for Rutherrin, working capital and general corporate purposes
Private placement of units
Dec 23, 2025 · US$973,842
Closed: C$1.33M raised · C$0.17 a unit · 1 warrant at C$0.21 for 60 months · free to trade Apr 24, 2026
Use of proceeds: Phase II NMIBC clinical study, working capital and general corporate purposes
Private placement of units
Dec 12, 2025 · US$3.19M
Cancelled: C$4.5M–C$5.5M · C$0.17 a unit · 1 warrant at C$0.21 for 60 months · Research Capital Corporation
Dealers: Research Capital Corporation (lead)
Use of proceeds: Phase II bladder cancer clinical study, GLP toxicology studies for intravenous Rutherrin, working capital and general corporate purposes
Private placement of units
Jul 28, 2025 · US$490,146
Closed: C$672,627 raised · C$0.2 a unit · 1 warrant at C$0.3 for 60 months · free to trade Nov 29, 2025
Insiders: An aggregate of 130,000 Units, representing gross proceeds of $26,000, were issued to certain insiders
Use of proceeds: Phase II NMIBC clinical study, development of Rutherrin, working capital and general corporate purposes
Decks
Investor Presentation (October 2026)
Investor deck · 16 slides · Oct 22, 2026
Investor Presentation (October 2026)
Investor deck · 16 slides · Oct 15, 2026
Investor Presentation (February 2026)
Investor deck · 21 slides · Feb 17, 2026
Investor Presentation (November 2025)
Investor deck · 20 slides · Nov 14, 2025
Theralase Technologies Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 33 in the last 12 months · 240 in all · newest Oct 26, 2026 · oldest 2017
- Calls
- 1 call with a replay · 1 with a transcript · latest Sep 3, 2026
- Decks
- 17 decks · latest Oct 22, 2026
Where Theralase Technologies Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:TLT · Home listing · This page | TSXV | Canada | CAD |
| OTC:TLTFF | OTC | United States | USD |
| Cboe Canada:TLT | Cboe Canada | Canada | CAD |
| Lang & Schwarz:A0DLB7 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A0DLB7 | LS Exchange | Germany | EUR |
| Frankfurt:TTX | Frankfurt | Germany | EUR |
| Stuttgart:TTX | Stuttgart | Germany | EUR |
| Dusseldorf:TTX | Dusseldorf | Germany | EUR |
Log in to ask 6ix AI your own questions about Theralase Technologies Inc.